HALO News and Press, Halozyme Therapeutics Inc. From 11/08/23

2023-11-08 05:19:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly...

2023-11-06 20:18:11 ET Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer...

2023-11-06 16:09:27 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q3 Non-GAAP EPS of $0.75 beats by $0.04 . Revenue of $216M (+3.4% Y/Y) in-line. Sees 2023 Non-GAAP diluted earnings per share of $2.70 to $2.80. Sees 2023 EBITDA of $430 million to $44...

HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and...

2023-11-06 08:23:39 ET More on Acumen Pharmaceuticals, Halozyme Therapeutics, etc. Navigating Acumen's Alzheimer's Risk And Reward Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA ...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Halozyme Therapeutics Inc. (HALO) is expected to report $0.67 for Q3 2023

Halozyme To Report Third Quarter 2023 Financial and Operating Results PR Newswire SAN DIEGO , Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating resu...

2023-10-27 08:47:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The quest to uncover the next big success story is an ongoing pursuit for investors. Three companies are captivating exemplars of success for those seeking to turn a modest investment into a fi...

2023-10-19 07:49:48 ET More on Bristol-Myers, Halozyme, etc. Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? Bristol Myers' Opdivo gets...